IGF-1 LR3

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a recombinant analog of human IGF-1 belonging to the insulin/IGF superfamily of peptide hormones. The native IGF-1 molecule is a 70-amino-acid single-chain polypeptide produced primarily in the liver in response to growth hormone (GH) stimulation. The LR3 variant was originally developed for research and cell culture applications — particularly for serum-free media formulations — and carries two deliberate structural modifications: an arginine substitution at position 3 (which disrupts high-affinity binding to IGF-binding proteins, or IGFBPs) and an added 13-amino-acid N-terminal extension. The result is a molecule with approximately 2–3x greater potency than native IGF-1 in some bioassays and a half-life extended to an estimated 20–30 hours compared to IGF-1's endogenous half-life of minutes to a few hours. For educational purposes only — the following is a research summary, not medical advice or a recommendation for human use.

Mechanistically, IGF-1 LR3 binds to the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase expressed in virtually all tissues. Upon binding, IGF-1R autophosphorylates and activates downstream signaling cascades including the PI3K/AKT/mTOR pathway — which promotes protein synthesis, cellular proliferation, and glucose uptake — and the MAPK/ERK pathway, which governs cell differentiation and survival. Because IGFBPs ordinarily sequester circulating IGF-1, limiting its bioavailability, the reduced IGFBP affinity of LR3 means a greater proportion of the administered molecule remains in free, receptor-accessible form. Animal and in vitro research also demonstrates IGF-1 LR3's ability to inhibit apoptosis and promote satellite cell activation in muscle tissue, which has made it a subject of interest in muscle-wasting disease research.

The evidence base for IGF-1 LR3 as a research compound in humans is sparse and must be characterized honestly. The bulk of published mechanistic work comes from in vitro cell culture studies and rodent models, where IGF-1 LR3 has been shown to promote skeletal muscle hypertrophy, accelerate wound healing, and improve glucose metabolism markers. A limited number of clinical studies have explored native IGF-1 (mecasermin) in conditions such as Laron syndrome and ALS, but these use a distinct molecule and a distinct administration context. No peer-reviewed randomized controlled trials specifically evaluating IGF-1 LR3 in healthy human subjects for performance or body composition outcomes have been identified in the published literature as of this writing. User self-reports in biohacking and bodybuilding communities describe outcomes consistent with anabolic and anti-catabolic effects — including accelerated muscle recovery, improved body composition, and enhanced vascularity — but these reports are anecdotal, uncontrolled, and carry significant confounding factors. They should not be interpreted as clinical evidence.

Dosing ranges reported in preclinical and cell culture research contexts vary considerably. In animal studies, IGF-1 LR3 doses have ranged from approximately 20 mcg/kg to over 100 mcg/kg depending on the model and endpoint. In the self-reported human research community, doses cited in anecdotal literature typically range from 20 mcg to 120 mcg per administration, often described as subcutaneous or intramuscular injection, with cycle lengths of 4–6 weeks commonly referenced. These figures are reported here solely because they appear in the publicly available research and discussion literature — they are not a recommendation, protocol, or endorsement of human use. Anyone administering this compound outside a licensed research context assumes full legal and medical risk.

From a legal and sourcing standpoint, IGF-1 LR3 occupies a complex position. In the United States, it is not FDA-approved for any human indication, is not a DEA-scheduled controlled substance, and exists in a regulatory gray area as a research chemical — legal to purchase for laboratory use but not for human consumption or sale as a drug or supplement. In the UK, it is not MHRA-approved and falls under research chemical regulations; importing or selling for human use would likely trigger Medicines Act provisions. In Australia, any form of IGF-1 is listed on the Prohibited Substances List by ASADA for athletes and is treated as a prescription-only substance under TGA scheduling. Vendors supplying this compound should be evaluated rigorously: COAs (Certificates of Analysis) from third-party labs confirming sequence accuracy via HPLC and mass spectrometry, verified purity above 98%, and endotoxin testing are minimum credibility markers. Lyophilized powder requires reconstitution with bacteriostatic water and cold-chain storage.